1492 Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

1492 Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-243	Closed	-$255K	–	120
2024 Q3	$255K	Sell	243 -5	-2%	-$5.56K	0.13%	77
2024 Q2	$261K	Buy	248 +23	+10%	+$22.3K	0.15%	72
2024 Q1	$217K	Sell	225 -13	-5%	-$12.4K	0.12%	86
2023 Q4	$209K	Sell	238 -11	-4%	-$9.06K	0.12%	93
2023 Q3	$205K	Buy	+249	New	+$196K	0.13%	86
2023 Q2	–	Sell	-249	Closed	-$205K	–	113
2023 Q1	$205K	Buy	+249	New	+$188K	0.13%	93
2022 Q4	–	Sell	-301	Closed	-$207K	–	120
2022 Q3	$207K	Buy	+301	New	+$189K	0.15%	94

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

1492 Capital Management's REGN Position: Q4 2024 in Review

1492 Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 243 shares — an estimated $255K sold.

1492 Capital Management first reported a position in REGN in Q3 2022 and held it in 7 quarters. The position peaked at $261K in Q2 2024. 1,320 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

1492 Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
1492 Capital Management sold 243 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $255K.
1492 Capital Management first reported a position in Regeneron Pharmaceuticals in Q3 2022 and held it in 7 quarters.
1492 Capital Management's Regeneron Pharmaceuticals position peaked at $261K in Q2 2024.
1,320 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on 1492 Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.